Jose Henao, MD
Nephrology · Las Cruces, NMNPI 1275067613
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,725 of the $30,860 with a category attached, or 73.6%. Amgen accounts for 86.2% of it on its own, with 27 other manufacturers making up the rest. Among nephrology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $188.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$27K
- Ardelyx, Inc.$596
- Bayer$454
- Mallinckrodt Hospital Products Inc.$439
- AstraZeneca$400
- Travere Therapeutics, Inc.$275
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$22,72574%
- Travel & lodging$2,7349%
- Food & beverage$5,32717%
- Education$740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 46 | $26,607 |
| Ardelyx, Inc. | 18 | $596 |
| Bayer | 17 | $454 |
| Mallinckrodt Hospital Products Inc. | 6 | $439 |
| AstraZeneca | 6 | $400 |
| Travere Therapeutics, Inc. | 7 | $275 |
| Otsuka America Pharmaceutical, Inc. | 9 | $271 |
| Aurinia Pharma U.S., Inc. | 9 | $265 |
| GSK | 6 | $161 |
| Medtronic | 1 | $160 |
| Boehringer Ingelheim | 3 | $157 |
| Electromed, Inc. | 6 | $148 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Merit Medical Systems Inc | 1 | $109 |
| Novo Nordisk | 5 | $104 |
| Baxter Healthcare | 2 | $97 |
| Calliditas Therapeutics US Inc. | 2 | $95 |
| Novartis | 4 | $78 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Apellis Pharmaceuticals, Inc. | 2 | $50 |
| Scpharmaceuticals Inc. | 2 | $41 |
| Ascendis Pharma Endocrinology Inc | 2 | $32 |
| AbbVie | 2 | $31 |
| United Therapeutics Corporation | 1 | $30 |
| Bard Peripheral Vascular, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavneos$25,920
- ACTHAR$275
- LOKELMA$247
- ELLIPSYS VASCULAR ACCESS SYSTEM$160
- JARDIANCE$125
- INJECTAFER$125
- Kerendia$125
- LUPKYNIS$125
- XPHOZAH 30 MG$121
- Wrapsody Stent Graft$109
- Filspari$104
How this compares
$30,860 in reported general payments places this provider in the 90th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 66 | $55,611 |
| FarxigaDapagliflozin Propanediol | 40 | $38,530 |
| KerendiaFinerenone | 23 | $26,521 |
| Torsemide | 45 | $894 |
| Potassium Chloride | 33 | $806 |
| Losartan Potassium | 46 | $183 |
| Carvedilol | 22 | $168 |
| Furosemide | 21 | $116 |
| Cefdinir | 13 | $109 |
| Lisinopril | 13 | $71 |
| Amlodipine Besylate | 14 | $68 |
| Allopurinol | 14 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $157 | $55,61166 claims |
| AstraZenecaFarxiga | $400 | $38,53040 claims |
| BayerKerendia | $454 | $26,52123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 68 nephrology providers in New Mexico.
Other nephrology in Las Cruces
- Claudio Perez-LedezmaLas Cruces$4K
- Nduka Obi OssaiLas Cruces$1K
- Osvaldo DelavegaLas Cruces$1K
- Lucia CorroLas Cruces$1K
- Satyaki BanerjeeAlbuquerque$260K
- Catalina VoinescuSanta Fe$41K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.